Search Close Search
Page Menu

Select Publications

Lee, J.-S., M.W. Lero, J. Mercado-Matos, S. Zhu, M. Jo, C.E. Tocheny, J.S. Morgan and L.M. Shaw. The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2/PI3K-mediated regulation of MYC. 2022. Cell Reports. 41(10)

Lee, J.-S., C.E. Tocheny and L.M. Shaw. The insulin-like growth factor signaling pathway in breast cancer: an elusive therapeutic target. 2022. Life. 12(12) 

Shaw, L.M.  2021. TBK1 has a new Akt. J. Biol. Chem.,

 Lero, M.W. and L.M. Shaw.  2021. Diversity of insulin and IGF signaling in breast cancer: implications for therapy. Mol. Cell. Endocrinol., doi:10.1016/j.mce.2021.111213

Carlisle, A.E., N. Lee, N., A.N. Matthew-Onabanjo, M. Spears, S.J. Park, D. Youkana, M.B. Doshi, A. Peppers, R. Li, A.B. Joseph, M. Smith, K. Simin, L.J. Zhu, P.L. Greer, L.M. Shaw, and D. Kim. 2020. Selenium detoxification is required for cancer cell survival.  Nat. Metab., 2:603-611

Matthew-Onabanjo, A.N., J. Janusis, J. Mercado-Matos, A.E. Carlisle, D. Kim, F. Levine, P. Cruz-Gordilla, R. Richards, M. Lee and L.M. Shaw. 2020. Beclin 1 promotes endosome recruitment of hepatocyte growth factor tyrosine kinase substrate (HRS) to suppress tumor proliferation. Cancer Research, 80:249-262

Piper, A.J., J.L. Clark, J. Mercado-Matos, A.N. Matthew-Onabanjo, C.-C. Hsieh, A. Akalin and L.M. Shaw. 2019. Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC). PLoS One, 14(8): e0220567.

Mercado-Matos, J., J. Janusis, S. Zhu, S. Chen and L.M. Shaw. 2018. Identification of a novel invasion-promoting region in Insulin Receptor Substrate 2 (IRS2). Mol. Cell. Biol., 38(14): e00590-17. doi:10.1128/MCB.00590-17

Zhu, S.*, B.M. Ward*, J. Yu, A.N. Matthew-Onabanjo, J. Janusis, C.-C. Hsieh, K. Tomaszewicz, L. Hutchinson, L.J Zhu, D. Kandil, and L.M. Shaw. 2018. Novel IRS2 mutations contribute to pleomorphic invasive lobular breast cancer. JCI Insight, 3(8): e97398 doi:10.1172/jci.insight. 97398

Mercado-Matos, J., J.L. Clark, A.J. Piper, J. Janusis and L.M. Shaw. 2017. Differential involvement of the microtubule cytoskeleton in Insulin Receptor Substrate-1 (IRS-1) and IRS-2 signaling to AKT determines response to microtubule disruption in breast carcinoma cells. J. Biol. Chem. 292:7806-7816

Mercado-Matos, J., A.N. Matthew-Onabanjo and L.M. Shaw. 2017. RUNX1 and breast cancer. Oncotarget (News Commentary). 8:17610-27. doi: 10.18632/oncotarget.15381

Becker, MA, Y.H. Ibrahim, A.S Oh, D.H. Fagan, S.A. Byron, A.L. Sarver, A.V. Lee, L.M. Shaw, C. Fan, C.M. Perou and D. Yee. 2016. Insulin receptor substrate adaptor proteins mediate prognostic gene expression profiles in breast cancer. PLoS One, 11(3): e0150564. DOI:10.1371/ journal.pone.0150564

Rohatgi, R.A. and L.M. Shaw. 2016. Autophagy-independent function of Beclin 1 in cancer. Mol. Cell. Oncol. 3:1, e1030539, DOI:10.1080/23723556.2015.1030539

 Browne, G, H, Taipaleenmaki, N.M. Bishop, S.C. Madasu, L.M. Shaw, A.J. van Wijnen, J.L. Stein, G.S. Stein and J.B. Lian. 2015. Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion. J. Cell. Physiol., 230:2522-2532

Rohatgi, R.A., J. Janusis, D. Leonard, K.D. Bellve, K.E. Fogarty, E.H. Baehrecke, S. Corvera and L.M. Shaw. 2015. Beclin 1 regulates growth factor receptor signaling in breast cancer. Oncogene. 34:5352-5362

Rahman, M., N.K. Nirala, A. Singh, L.J. Zhu, T. Bamba, E. Fukusaki, L.M. Shaw, D.G. Lambright, J.K. Acharya and U.R. Acharya. 2014. Drosophila Sirt2/mammalian SIRT3 deacetylates ATP synthase-b and regulates mitochondrial Complex V activity. J. Cell Biol. 206:289-305

Walavalkar V., J. Clark, D. Kandil, S. Lu, K. Edmiston, L.M. Shaw, and A. Khan. 2014. Correlation of Oncotype DX recurrence score with the expression of Insulin Receptor Substrate (IRS) proteins in ER+ breast cancer. J. Cancer Genetics and Biomarkers. 1:1-11

Landis, J. and L.M. Shaw. 2014. IRS-2 mediated PI3K signaling selectively inhibits GSK-3b to regulate breast carcinoma cell metabolism. J. Biol. Chem. 289:18603-18613

Goel, H.L., T. Gritsko, B. Pursell, C. Chang, L.D. Schultz, D.L. Griener, R. Toftgard, L.M. Shaw and A.M. Mercurio. 2014. Regulated Splicing of the a6 integrin cytoplasmic domain determines the fate of breast cancer stem cells and tumor initiation. Cell Reports. 7:747-76